The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.
- Resource Type
- journal article
- Authors
- Li, Yijian; Gao, Qianqian; Liu, Huan; Lin, Shufen; Chen, Huanyi; Ding, Renpeng; Gu, Ying; Chao, Cheng-chi; Dong, Xuan
- Source
- Cancer Investigation. Apr2021, Vol. 39 Issue 4, p285-296. 12p.
- Subject
- *IMMUNE checkpoint inhibitors
*EPIDERMAL growth factor
*CELLULAR therapy
*MONOCLONAL antibodies
*ANTINEOPLASTIC agents
*CELL receptors
*EARLY detection of cancer
*GENE expression
*INTERFERONS
*MEMBRANE proteins
*CELL lines
*T cells
*IMMUNOTHERAPY
*PHARMACODYNAMICS
- Language
- ISSN
- 0735-7907
The switchable chimeric antigen receptors (CARs) have shown many advantages in CAR T-cell therapy. However, human primary T-cells are required to evaluate antigen-specific adaptors by IFN-γ assay or FACS analysis, which limits the throughput of adaptor screening. A sensitive and robust CD16-CAR Jurkat NFAT-eGFP reporter system has been developed to assess the therapeutic efficacy of antibody-targeted CAR-T-cell by effectively evaluating the T-cell activation by various tumor cells and the impact of immune checkpoint inhibitor antibodies. This reporter system facilitates the screening of targeted antibodies in a high throughput manner for the development of improved T-cell immunotherapy. [ABSTRACT FROM AUTHOR]